Amgen Q1 2025 Update: Financials and Product Performance
Ticker: AMGN · Form: 10-Q · Filed: 2025-05-02T00:00:00.000Z
Sentiment: neutral
Topics: financials, earnings, debt, biotech
Related Tickers: AMGN
TL;DR
Amgen Q1 2025: Revenue up, debt stable, key product sales detailed.
AI Summary
Amgen Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's financial statements include details on common stock, A2.00 Senior Notes Due 2026, and product revenues for the first quarter of 2025 and 2024. Key balance sheet figures as of March 31, 2025, and December 31, 2024, are also presented, including common stock, retained earnings, and accumulated other comprehensive income.
Why It Matters
This filing provides investors with a snapshot of Amgen's financial health and revenue generation from its products in early 2025, crucial for assessing the company's ongoing performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags or significant negative developments indicated.
Key Numbers
- 2025-03-31 — End of Q1 2025 (Reporting period end date)
- 2024-12-31 — End of Q4 2024 (Prior period balance sheet date)
- 2025-01-01 — Start of Q1 2025 (Reporting period start date)
Key Players & Entities
- AMGEN INC (company) — Filer
- 20250331 (date) — Period of Report
- 20250502 (date) — Filed as of Date
- A2.00 Senior Notes Due 2026 (dollar_amount) — Debt Instrument
FAQ
What were Amgen's product revenues for the first quarter of 2025 compared to the first quarter of 2024?
The filing indicates product revenues for the period January 1, 2025, to March 31, 2025, and compares them to the period January 1, 2024, to March 31, 2024.
What is the principal amount of the A2.00 Senior Notes Due 2026?
The filing references the 'A2.00 Senior Notes Due 2026' for the period January 1, 2025, to March 31, 2025, but the specific principal amount is not detailed in the provided text.
What are the key components of Amgen's equity as of March 31, 2025?
As of March 31, 2025, Amgen's equity includes common stock, retained earnings, and accumulated other comprehensive income, with specific values detailed for December 31, 2024, and implied for March 31, 2025.
What is Amgen's fiscal year end?
Amgen's fiscal year ends on December 31.
What is the filing date for this 10-Q report?
This 10-Q report was filed as of May 2, 2025.
From the Filing
0000318154-25-000020.txt : 20250502 0000318154-25-000020.hdr.sgml : 20250502 20250501185446 ACCESSION NUMBER: 0000318154-25-000020 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 82 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250502 DATE AS OF CHANGE: 20250501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 25905015 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 10-Q 1 amgn-20250331.htm 10-Q amgn-20250331 0000318154 false 2025 Q1 12/31 http://fasb.org/srt/2024#PartnershipInterestMember http://fasb.org/srt/2024#PartnershipInterestMember xbrli:shares iso4217:USD iso4217:USD xbrli:shares amgn:segment xbrli:pure amgn:notice amgn:case iso4217:EUR iso4217:GBP 0000318154 2025-01-01 2025-03-31 0000318154 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000318154 amgn:A2.00SeniorNotesDue2026Member 2025-01-01 2025-03-31 0000318154 2025-04-28 0000318154 us-gaap:ProductMember 2025-01-01 2025-03-31 0000318154 us-gaap:ProductMember 2024-01-01 2024-03-31 0000318154 us-gaap:ProductAndServiceOtherMember 2025-01-01 2025-03-31 0000318154 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-03-31 0000318154 2024-01-01 2024-03-31 0000318154 2025-03-31 0000318154 2024-12-31 0000318154 us-gaap:CommonStockMember 2024-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-12-31 0000318154 us-gaap:RetainedEarningsMember 2024-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000318154 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0000318154 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000318154 us-gaap:CommonStockMember 2025-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2025-03-31 0000318154 us-gaap:RetainedEarningsMember 2025-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0000318154 us-gaap:CommonStockMember 2023-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-12-31 0000318154 us-gaap:RetainedEarningsMember 2023-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000318154 2023-12-31 0000318154 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000318154 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000318154 us-gaap:CommonStockMember 2024-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-03-31 0000318154 us-gaap:RetainedEarningsMember 2024-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000318154 2024-03-31 0000318154 us-gaap:ProductMember amgn:ReportableSegmentMember 2025-01-01 2025-03-31 0000318154 us-gaap:ProductMember amgn:ReportableSegmentMember 2024-01-01 2024-03-31 0000318154 us-gaap:ProductAndServiceOtherMember amgn:ReportableSegmentMember 2025-01-01 2025-03-31 0000318154 us-gaap:ProductAndServiceOtherMember amgn:ReportableSegmentMember 2024-01-01 2024-03-31 0000318154 us-gaap:OperatingSegmentsMember amgn:ReportableSegmentMember 2025-01-01 2025-03-31 0000318154 us-gaap:OperatingSegmentsMember amgn:ReportableSegmentMember 2024-01-01 2024-03-31 0000318154 us-gaap:CorporateNonSegmentMember amgn:R